ISSN:
1437-7772
Keywords:
Key words Renal cell carcinoma
;
Interleukin-2
;
Interleukin-12
;
T-helper subset
;
Immunity
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background. We studied the anti-tumor effectiveness of treatment with interleukin-2 (IL-2) and/or IL-12 for a spontaneously arising murine renal cell carcinoma (RC-2). We also analyzed the immunological effects induced by the treatments. Methods. One week after RC-2 inoculation, treatment with IL-2 (1 × 104 U or 5 × 104 U/mouse, every day for 3 weeks) and/or IL-12 (1 μg/mouse, once a week for 3 weeks) were started. We analyzed the relative mean tumor weight ratio (tumor relative weight/control relative weight [TRW/CRW]), the degree of tumor degeneration (grade), and the survival rate of the mice. We also analyzed the expression of various T-helper (Th)1-derived cytokine mRNAs (interferon-γ, IL-2, tumor necrosis factor-β) and Th2-derived-cytokines mRNAs (ILs-4, 5, 6, 10) in the spleen by reverse transcription-polymerase chain reaction. Results. The combination treatments were effective in terms of the TRW/CRW ratios (4.8% for IL-2 5 × 104 U/mouse plus IL-12 and 8.9% for IL-2 1 × 104 U/mouse plus IL-12) and showed superior survival of mice compared with results for the control mice and those treated with a single agent. However, a small amount of viable tumor cells still remained (grade IIb), indicating the treatment was ineffective. Control spleens expressed Th2-derived cytokine mRNAs predominantly, in accordance with tumor growth. In mice that had combination treatments, the spleen expressed Th1-derived cytokine mRNAs, except for IL-10. Conclusion. We conclude that combination treatment with IL-2 and IL-12 has potent anti-tumor effectiveness, based upon the induction of cellular immunity implying cross-regulation with humoral immunity.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/s101470050086
Permalink